News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - IND
Epizyme (EPZM) Announces FDA Acceptance Of Investigational New Drug Application For Tazemetostat In Mesothelioma 5/4/2016
Corium International, Inc. Announces Streamlined Bioequivalence Development Path For Transdermal Corplex Donepezil Following Positive Pre-IND Communication From FDA 5/3/2016
Tesaro (TSRO) Announces Submission Of Investigational New Drug Application For Anti-TIM-3 Antibody TSR-022 To The FDA 4/25/2016
NanoCor Therapeutics Announces FDA Acceptance Of Investigational New Drug (IND) For Carfostin 4/20/2016
Selvita Files IND Application For Its Novel, Dual PIM/FLT3 Inhibitor In AML 4/18/2016
Neovacs Obtains South Korea Health Authority Approval For IND Application With Infa Kinoid In Lupus 4/14/2016
Adaptimmune (ADAP) Announces FDA Acceptance Of IND Application For Affinity Enhanced T-Cell Therapy Targeting AFP In Liver Cancer 4/7/2016
CANBridge Life Sciences Submits Investigational New Drug Application To Taiwan Food And Drug Administration For CAN-008 Phase I/II Trial In Glioblastoma 4/7/2016
Hansa Medical: FDA Clears Hansa Medical’s IND Application For IdeS In Kidney Transplantation 4/4/2016
Evofem Files IND For Evaluation Of Prevention Of Recurrence Of Bacterial Vaginosis 3/31/2016
Regen BioPharma Submits IND Application To FDA On tCellVax, A Checkpoint Inhibitor For Cancer Therapy 3/23/2016
FDA Lifts Partial Clinical Hold on Medivation (MDVN)'s Pidilizumab 3/9/2016
Titan Pharma (TTP) Receives Feedback From FDA On Ropinirole Implant Development Program For Parkinson's Disease 3/8/2016
3SBio Inc. (SSRX)'s PEG-irinotecan Wins IND Approval From China FDA 3/7/2016
KemPharm Files IND For KP511, An Investigational Prodrug Of Hydromorphone 3/7/2016
InDex Pharmaceuticals AB Receives FDA Clearance Of IND For Cobitolimod (Kappaproct) Phase IIb Trial 3/7/2016
CTD Holdings, Inc.' Clinical Program To Move Forward In The U.S. 2/29/2016
Portage Biotech's Biohaven Announces Expedited Development Path For BHV-0223 Following Successful Pre-IND Interaction With FDA 2/25/2016
Patient Deaths Push the FDA to Slap Full Clinical Hold on CTI BioPharma's Cancer Drug Pacritinib 2/10/2016
FDA Slaps Partial Clinical Hold on CTI BioPharma's Lead Product Candidate Pacritinib, Stock Crumbles 2/9/2016
Sangamo (SGMO) Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS I 2/8/2016
Acura Pharmaceuticals, Inc. (ACUR) Provides Development Update On Its LIMITX Abuse Deterrent Technology 2/2/2016
With Almost $200 Million in the Bank, WAVE Life Sciences (WVE) Plans Six Clinical Programs in Three Years 2/1/2016
Ariad (ARIA) Announces FDA Clearance To Begin Clinical Development Of AP32788 2/1/2016
Fate Therapeutics (FATE) Announces FDA Clearance Of Investigational New Drug Application For Protmune For Prevention Of Acute Gvhd And CMV Infection 1/27/2016
XTL Biopharmaceuticals Ltd. (XTLB) Announces Encouraging Feedback From U.S. FDA On Its Upcoming IND Filing For Lupus Drug Hcdr1 1/25/2016
Athenex Announces US FDA Allowance Of The Investigation New Drug Application Of Oradoxel, The Proprietary Oral Form Of Docetaxel 1/25/2016
Collegium (COLL) Announces FDA Acceptance Of IND Application For Abuse-Deterrent, Hydrocodone Deterx 1/21/2016
MultiCorp International, Inc. To Develop 4 Arm Study For Emergency Room Clinical Trials With Patented Migraine Medicine 1/21/2016
Tricida Announces FDA Acceptance Of Investigational New Drug Application For Lead Candidate TRC101 And Hiring Of Claire Lockey As Chief Development Officer And Edward J. Hejlek As General Counsel 1/13/2016
Juniper Pharma (JNP) Expands Lead Phase 2b Trial, Submits Pre-IND Meeting Request For Its First Intra-Vaginal Ring Product, And Adds Four Key Executives 1/11/2016
XTL Biopharmaceuticals Ltd. (XTLB) Submits Protocol To Yeda For Advanced Clinical Trial Of hCDR1 In The Treatment Of Lupus 1/11/2016
Evofem Holdings Announces Successful Completion Of Pre-IND Meeting For Amphora 1/11/2016
BeiGene Release: U.S. IND Becomes Active For BGB-A317, An Anti-PD-1 Monoclonal Antibody 1/11/2016
Prescient Therapeutics Release: FDA Allows PTX IND For Leukemia Phase Ib & II Trials 1/8/2016
Aeglea Announces FDA Acceptance Of Its Investigational New Drug Application For AEB1102 For The Treatment Of Arginase I Deficiency 1/7/2016
MabVax Therapeutics, Inc. Files IND For A Phase I Clinical Trial With 89Zr-Humab-5B1 1/6/2016
Vyome Biosciences Announces FDA Acceptance Of Investigational New Drug Application In The US For Its Lead Product VB-1953 To Treat Moderate-To-Severe Acne 1/6/2016
Lion Biotech Submits Investigational New Drug Application To Conduct Studies In Cervical, Head And Neck Cancer 1/4/2016
Nanobiotix Release: FDA Approved Investigational New Drug For NBTXR3 In A New Clinical Study In Prostate Cancer 1/4/2016
Minerva Neurosciences, Inc. (NERV): Enrollment Completed In MIN-101 EU Phase IIb Trial, IND Application Accepted By FDA 12/30/2015
Saronic Biotech Files Investigational New Drug Application With FDA For SBI1997 Phase I/II Clinical Trial 12/18/2015
FDA Lifts Advaxis (ADXS) Clinical Hold 12/16/2015
NephroGenex (NRX) Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury 12/14/2015
X4 Pharma Announces FDA Allowance Of X4P-001 IND For Phase 1b/2a Study Of In Refractory Clear Cell Renal Cell Carcinoma 12/14/2015
Zafgen (ZFGN) Plunges Some More After FDA Orders Full Clinical Hold on Beloranib 12/3/2015
Sangamo BioSciences (SGMO) Announces FDA Clearance Of Investigational New Drug Application For SB-FIX, First In Vivo Protein Replacement Platform Program For Treatment Of Hemophilia B 12/1/2015
Galmed Pharmaceuticals Announces FDA Clearance Of IND Of Aramachol For The Treatment Of Patients With HIV-Associated Lipodystrophy And Nonalcoholic Fatty Liver Disease 12/1/2015
Sunesis (SNSS) Announces First Patient Treated In Indiana University Pilot Study Of Vosaroxin And Cytarabine In Adults Age 60 Years And Older With Previously Untreated AML 12/1/2015
MabVax Therapeutics, Inc. Files IND For Phase I Clinical Trial With Humab 5B1 As A Therapeutic For Pancreatic Cancer 12/1/2015
Rich Pharma Announces Additional Submission To The FDA 11/23/2015
Glaukos Submits IND Application To FDA To Study iDose Travoprost Intraocular Implant In Glaucoma Patients 11/20/2015
Aduro Biotech (ADRO) Receives Milestone Payment From Janssen Pharmaceutical For Submission Of Investigational New Drug Application For ADU-741 In Prostate Cancer 11/18/2015
Oragenics, Inc. (OGEN) Announces Successful Completion Of Pre-IND Meeting For OG253 11/18/2015
Regen BioPharma Submits Response To FDA Questions On Hemaxellerate Investigational New Drug Application 11/17/2015
Viking Therapeutics (VKTX) Submits Investigational New Drug (IND) Application To Conduct Phase 2 Clinical Trial Of VK2809 In Patients With Hypercholesterolemia And Fatty Liver Disease 11/17/2015
aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine For GMP Process Development And For Potential Treatment Of Severe Lung Diseases 11/11/2015
Immune Pharma Announces FDA Acceptance Of Investigational New Drug (IND) Application In The U.S. For Bertilimumab For The Treatment Of Bullous Pemphigoid 11/9/2015
Theravance Biopharma (TBPH) Submits Investigational New Drug (IND) Application For TD-1473, A GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 11/3/2015
AGTC (AGTC) Files Investigational New Drug Application For The Treatment Of Achromatopsia Caused By Mutations In The CNGB3 Gene 11/2/2015
TetraLogic Pharmaceuticals (TLOG) Announces The Opening Of An IND For SHAPE Gel In Alopecia Areata 11/2/2015
Daiichi Sankyo and Bay Area’s Plexxikon Inc. Win Breakthrough Tag for Pexidbartini 11/2/2015
Tyme Technologies Receives FDA Acceptance Of Investigational New Drug Application For Oncology Drug Candidate, SM-88 10/27/2015
Turing Pharmaceuticals AG Announces FDA Acceptance Of Investigational New Drug Application And Fast Track Designation For TUR-004 10/23/2015
Can-Fite BioPharma (CFBI) Release: New Study Demonstrates CF602 Mechanism Of Action To Improve Sexual Dysfunction 10/22/2015
CytoDyn Files An IND And Full Protocol For Phase II Study In GvHD 10/20/2015
Galectin' GR-MD-02 To Be Studied In Combination With Keytruda In Patients With Metastatic Melanoma 10/19/2015
Inovio Pharma (INO) And Partner Advance MERS Vaccine 10/19/2015
Theravance Biopharma (TBPH) Submits Investigational New Drug (IND) Application For TD-0714, An Inhibitor Of Neprilysin (NEP) 10/13/2015
Nektar Therapeutics (NKTR) Chief Science Officer Provides Details on Immuno-Oncology, Pain Pipelines 10/13/2015
Immune Pharmaceuticals, Inc. Submits Investigational New Drug Application (IND) In The U.S. For Its Lead Product Candidate Bertilimumab For The Treatment Of Bullous Pemphigoid 10/7/2015
Rich Pharmaceuticals Retains Theradex® To Finalize Investigational New Drug Application And Initiate Next Phases Of Clinical Trials 10/7/2015
Kadimastem Submitted Pre-IND Package To The FDA 10/7/2015
Otonomy (OTIC) Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311 10/5/2015
Fibrocell Science, Inc. And Intrexon Provide Regulatory Update For FCX-007 For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 9/25/2015
ESSA Pharma Receives FDA Approval To Commence Clinical Development 9/24/2015
Aeglea Announces FDA Acceptance Of Investigational New Drug Application For AEB1102 9/14/2015
Dimension Therapeutics Announces FDA Acceptance Of Investigational New Drug Application And Orphan Drug Designation For Lead Candidate DTX101 In Patients With Hemophilia B 9/10/2015
Pluristem Therapeutics (PSTI) Completed Successful Meeting With The U.S. FDA In Preparation For Filing An IND For PLX-R18 To Treat Incomplete Hematopoietic Recovery After Bone Marrow Transplantation 9/9/2015
Dicerna (DRNA) Submits Investigational New Drug (IND) Application For DCR-PH1, An Investigational Therapy For Primary Hyperoxaluria Type 1 (PH1) 9/2/2015
Bionomics Limited (BNO.AX) Release: Successful BNC101 IND Submission Paves Way For Development Of Promising Cancer Stem Cell Drug Candidate 8/31/2015
Portage Biotech's PPL Will Advance Its Lead Candidate PPL-003 To An IND For Dry Eye Disease And Uveitis 8/31/2015
Portage Biotech's Biohaven's Lead Drug Candidate Clears FDA Investigational New Drug Application (IND) Review And Clinical Studies To Begin 8/24/2015
Epizyme (EPZM) Announces Acceptance Of Investigational New Drug Application For Tazemetostat In Patients With INI1-Negative Tumors Or Synovial Sarcoma 8/24/2015
RetroSense Therapeutics’ Lead Gene Therapy Candidate Gets FDA Clearance To Proceed To First-In-Human Clinical Trials 8/24/2015
TapImmune Inc. (TPIV) Completes Transfer of IND From The Mayo Clinic 8/18/2015
La Jolla Pharma (LJPC) Announces FDA Acceptance Of IND For LJPC-401 8/11/2015
Regen BioPharma Progresses In FDA Responses To dCellVax Clinical Trial Questions 8/10/2015
TRACON Pharmaceuticals, Inc. (TCON) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/6/2015
FDA OKs Juno (JUNO)'s IND for Lead Leukemia Candidate JCAR015 8/3/2015
Mundipharma EDO Gmbh Announces FDA Investigational New Drug Approval Of Its First Anti-Cancer Compound, EDO-S101, For The Treatment Of Patients With Relapsed/Refractory Haematologic Malignancies And Solid Tumours 7/31/2015
Ignyta (RXDX) Announces FDA Clearance Of IND For RXDX-107 7/29/2015
KaloBios Pharmaceuticals, Inc. (KBIO) Announces FDA Clearance Of Investigational New Drug Application For KB003 In Patients With Chronic Myelomonocytic Leukemia 7/29/2015
FibroGen, Inc. (FGEN) Receives FDA Clearance to Proceed With Clinical Study of FG-3019 in Duchenne Muscular Dystrophy 7/28/2015
Portage Biotech's Biohaven Announces IND Filing For Bhv-0223 For Phase 1 Clinical Testing 7/23/2015
Fibrocell Science, Inc. And Intrexon Announce IND Filing Of FCX-007 For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 7/20/2015
Goodwin Biotechnology, Inc. Announces The Completion Of cGMP Manufacturing Of An IgM Monoclonal Antibody And IgM : Ligand Conjugate For Q Therapeutics, Inc., And Successful Clearance Of Q Therapeutics' IND Submission For Q-Cells Cell Therapy In ALS 7/13/2015
Adaptimmune Announces FDA Acceptance Of Investigational New Drug (IND) Application For MAGE-A10 T In Patients With Non-Small Cell Lung Cancer 7/2/2015
TRACON Pharmaceuticals, Inc. (TCON) Announces IND Filing Of DE-122 (TRC105) For The Treatment Of Wet Age-Related Macular Degeneration By Santen Pharmaceutical 7/1/2015
Circadian Technologies Limited (CIR.AX) Commences Wet AMD OPT-302 Clinical Trial 7/1/2015
Juno Therapeutics (JUNO) Announces FDA Acceptance Of Investigational New Drug Application For JCAR017 In Relapsed/Refractory B Cell Non-Hodgkin Lymphoma 6/29/2015
TxCell Announces FDA Acceptance Of IND For Ovasave 6/29/2015
BeiGene Co.,Ltd Announces IND Approval For BGB-3111, A Bruton Tyrosine Kinase Inhibitor 6/19/2015
BiondVax Pharmaceuticals Announces FDA Acceptance Of IND Application For Its Investigational Universal Flu Vaccine 6/17/2015
Genticel Receives FDA Clearance Of IND Application For U.S. Phase I Clinical Trial Of GTL001 (Procervix), Company's First-In-Class HPV Therapeutic Vaccine Candidate 6/16/2015
Sucampo (SCMP) Release: China Food And Drug Administration Accepts IND For Pivotal Study Of AMITIZA (Lubiprostone) 6/16/2015
U.S. FDA Reactivates Prescient Therapeutics's IND For PTX-100 Breast Cancer Trial 6/10/2015
Stemedica Cell Technologies, Inc. Release: FDA Grants IND Approval For Phase Iia Clinical Trial Using Stemedica's itMSC Therapy To Treat Alzheimer's Disease 6/9/2015
Goodwin Biotechnology, Inc. And Aspyrian Therapeutics Collaborate On The Successful GMP Manufacturing And IND Submission For A Novel Antibody Drug Conjugate (ADC) Platform 6/9/2015
National Cancer Institute Accepts Rexahn Pharmaceuticals, Inc. (RNN)'s RX-21101 For Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program 6/8/2015
Q Therapeutics, Inc. Release: Novel Cellular Therapeutic Approach For ALS Gets FDA Clearance For First-In-Human Trials 6/4/2015
Advaxis, Inc. Announces FDA Clearance Of Investigational New Drug Application For Phase 2 Study Of ADXS-HPV And Incyte (INCY)'s Epacadostat For The Treatment Of HPV-Associated Early Stage Cervical Cancer 6/1/2015
ProLynx Announces Active IND Of A Novel Ultra-Long Acting PEG–SN-38 Conjugate To Treat Solid Tumors 6/1/2015
ASCO15: Affimed Therapeutics AG (AFMD) ASCO Data For The CD33/CD3-Tandab Program Demonstrate That CD33 And CD3 Binding Affinities Correlate With Potent T-Cell Activation And Cytotoxicity 5/29/2015
MicroBiome Therapeutics LLC Receives Positive Response From FDA For Use Of Expedited Regulatory Pathway For Diabetes Drug Nm505 5/12/2015
Aspyrian Therapeutics Inc. Announces FDA Acceptance Of An Investigational New Drug Application For RM-1929, A First-In-Class, Precision-Targeted Therapy For Cancer 5/12/2015
Gemmus Pharma Announces FDA Acceptance Of IND Application For GP1681 - A Novel Host-Based Drug Candidate For Influenza 5/11/2015
FDA Puts ESSA Pharma's IND on Clinical Hold 5/4/2015
C-FDA Approves IND For D-Pharm Ltd.'s Anti-Epileptic Drug, DP-VPA In China 4/14/2015
FDA Modifies Partial Clinical Hold On Tekmira (TKMR)'s TKM-Ebola IND To Allow Multiple Dosing Of Healthy Volunteers 4/10/2015
Anika Therapeutics (ANIK) Files IDE Application With U.S. FDA For Hyalofast 4/9/2015
ArmaGen Technologies, Inc. Announces FDA Acceptance Of IND Application For AGT-181 For The Treatment Of Hurler Syndrome 4/8/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
Prescient Therapeutics Receives Approval From U.S. FDA To Transfer IND Sponsorship For Lead Drug Candidate PTX-200 4/1/2015
Neurotech Announces FDA Acceptance Of Investigational New Drug Application And Clinical Trial Initiation Of Novel Therapy For Wet AMD 3/30/2015
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015
Investigational New Drug Application For WuXi PharmaTech Co., Ltd. MedImmune (AZN)'s Monoclonal Antibody Accepted For Review By CFDA 3/27/2015
Amarantus BioSciences, Inc. Opens Investigational New Drug (IND) Application With The U.S. FDA Allowing The Start Of A Phase 2b Program Of Eltoprazine In Parkinson's Disease Levodopa-Induced Dyskinesia 3/26/2015
Immunomic Therapeutics Receives Positive Feedback From FDA Following Pre-IND Discussions for Its Proprietary Peanut Allergy Vaccine 3/25/2015
FDA Accepts Invion Limited Proposal To Progress Development Of Inhaled Nadolol To Treat Chronic Respiratory Diseases 3/23/2015
BioPharmX Corporation Completes Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution 3/18/2015
Egalet Earns $10 Million Milestone Payment Triggered By Advancement Of Shionogi, Inc.'s Abuse-Deterrent, Extended-Release Hydrocodone, S-718632, Using Egalet's GuardianTechnology 3/17/2015
ADC Therapeutics Submits Its First IND For A Novel Antibody Drug Conjugate Against Lymphomas 3/16/2015
Cellceutix (CTIX) Advancing Treatment for Hidradenitis Suppurativa, Pre-IND Meeting Request To FDA 3/16/2015
BioBlast Pharma (ORPN) Receives IND Clearance To Commence Clinical Trial For Cabaletta For The Treatment Of OPMD 3/12/2015
Applied Genetic Technologies Corporation Files Investigational New Drug Application For The Treatment Of X-Linked Retinoschisis 3/10/2015
Corbus Pharmaceuticals, Inc.' IND Receives Clearance From FDA To Initiate Phase 2 Trials In Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab 3/9/2015
Mersana Therapeutics Nabs $35 Million And A New CEO 3/3/2015
Otic Pharma Announces Encouraging Feedback From A Pre-IND Meeting With The FDA 2/23/2015
Sangamo BioSciences, Inc. (SGMO) Announces FDA Acceptance Of IND To Initiate Clinical Trial Of Its Novel ZFP Therapeutic® For Beta-Thalassemia 2/4/2015
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia 2/4/2015
Lion Biotechnologies, Inc. Announces Allowance Of IND Application To Begin New Phase 2 Study In Metastatic Melanoma 2/2/2015
Lpath, Inc. (LPTN) Submits Investigational New Drug Application For Lpathomab For Neuropathic Pain 2/2/2015
Leading BioSciences Recieves FDA IND Clearance To Proceed With A Randomized, Multi-Center Phase 2 Clinical Trial Using Lb1148 To Treat Septic Shock 2/2/2015
MediciNova, Inc. Announces An Open Investigational New Drug (IND) Application For MN-001 In NASH 1/28/2015
Pharmalink Announces An Open Investigational New Drug (IND) Application For Nefecon® 1/21/2015
Celsus Therapeutics (CLTX) Announces FDA Allowance Of IND For Clinical Development Of MRX-6 Cream In Atopic Dermatitis 1/12/2015
Milestone Pharmaceuticals Receives FDA Clearance Of MSP-2017 Phase 2 IND 1/12/2015
BioPharmX Corporation Granted Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution 1/12/2015
Sirnaomics And Partner Submit IND To CFDA For Its First Anti-Fibrosis siRNA Therapeutic 1/5/2015
Aldeyra Therapeutics (ALDX) Submits IND Filing To FDA For Clinical Testing Of NS2 In Patients With Sjogren-Larsson Syndrome 1/5/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Partner Submits Phase 2B/3 IND To Korean Health Authority For RGN-259 For The Treatment Of Dry Eye Syndrome 12/29/2014
Kite Pharma, Inc. (KITE) Submits Investigational New Drug Application For Phase 1/2 Trial Of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, For The Treatment Of Refractory Aggressive Non-Hodgkin Lymphoma 12/23/2014
Matinas BioPharma Provides Update On Clinical Development Program For MAT9001 Following FDA Feedback On IND Submission 12/23/2014
FDA Accepts IND Application For Radius (RDUS)'s Investigational Drug RAD1901 Being Developed For Potential Use In Metastatic Breast Cancer 12/22/2014
Pfenex Inc. (PFNX) Announces Active IND And Additional BARDA Funding For Recombinant Anthrax Vaccine Program, Px563L 12/22/2014
Aldeyra Therapeutics (ALDX) Submits FDA IND Filing for Noninfectious Anterior Uveitis 12/18/2014
Portage's Biohaven Receives Response From FDA To Its Pre-IND Meeting Request 12/18/2014
HedgePath Pharmaceuticals Receives IND Clearance To Commence Development Of Its Proposed Cancer Treatment 12/16/2014
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence Clinical Trials Of ADXS-HPV In Combination With MedImmune (AZN)'s MEDI4736 For The Treatment Of HPV-Associated Cancers 12/15/2014
Synageva BioPharma (GEVA) Announces Active Investigational New Drug Application For SBC-103 For The Treatment Of Mucopolysaccharidosis IIIB 12/15/2014
Arrowhead Research Corporation (ARWR) Files IND For RNAi Therapeutic ARC-520 To Begin Phase 2b Multiple-Dose Studies In Chronic Hepatitis B Patients 12/15/2014
Batu Biologics Submits Investigational New Drug Application For Lung Cancer Anti-Angiogenic Immunotherapy With FDA 12/12/2014
ArmaGen Announces FDA Acceptance Of IND Application For AGT-182 for the Treatment Of Hunter Syndrome 12/11/2014
Boston Therapeutics, Inc. Announces FDA Acceptance Of IND To Initiate A Clinical Trial Of BTI-320 To Treat Type ll Diabetes And Weight Loss 12/11/2014
Lakewood-Amedex Inc. Submits Investigational New Drug Application For Bisphosphocin Nu-3 For The Treatment Of Diabetic Foot Infections 12/11/2014
KemPharm, Inc. Completes Pre-IND Meeting With FDA For NME Prodrug Of Hydromorphone, KP511 12/9/2014
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence Clinical Trials Of ADXS-PSA In Combination With Merck & Co. (MRK)'s KEYTRUDA® (Pembrolizumab) For Prostate Cancer 12/8/2014
BioPharmX Corporation Announces Submission Of Pre-IND Meeting Request To The U.S. FDA For Its Topical Acne Solution 12/3/2014
ContraFect Corporation (CFRXU) Submits Complete Response To IND Clinical Hold For CF-301 12/2/2014
Hovione Files its First Investigational New Drug Application With The FDA 12/1/2014
BioRestorative Therapies, Inc. Schedules Pre-IND Meeting With FDA 11/24/2014
Cesca Therapeutics Announces Filing Of U.S. Pivotal IDE Application For No-Option Critical Limb Ischemia ("CLI") 11/24/2014
HedgePath Pharmaceuticals Files IND Application 11/18/2014
Fibrocell Science, Inc. Announces IND Allowed To Proceed To Develop New Treatment For Wounded Warrior Amputees To Prevent Stump Skin Diseases 11/18/2014
CytoTools AG: Clinical Development Program For The Wound Healing Drug DermaPro® Now Extended To US Pharmaceuticals Market 11/17/2014
Leading BioSciences Submits Expanded Access, Compassionate Use IND For LB1148 To Treat Ebola-Related Shock And Multi-Organ Failure 11/6/2014
FDA Issues IND Number For Regen BioPharma 's dCellVax Therapeutic Application, A Proposed Treatment For Breast Cancer 11/4/2014
Geron Corporation (GERN) Soars As The FDA Removes Full Clinical Hold On Imetelstat 11/4/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS – FDA Response To Phase 2b Study Plans 10/24/2014
Rich Pharmaceuticals Announces Submission Of Investigational New Drug (IND) Application To FDA For The Treatment Of Acute Myelocytic Leukemia And Myelodysplastic Syndrome 10/23/2014
TONIX Pharmaceuticals, Inc. (TNXP) Receives IND Clearance For TNX-201 In Episodic Tension-Type Headache 10/21/2014
AbGenomics Corporation Announces IND Filing For Abgn-168H (Neihulizumab) To Treat Psoriatic Arthritis 10/17/2014
Regen BioPharma Files IND Application With FDA For dCellVax Breast Cancer Immune Therapy 10/8/2014
Ebola Patient Gets Chimerix, Inc. (CMRX) Drug, Clinical Trials Planned 10/7/2014
FDA Approves NeuroGenetic Pharmaceuticals, Inc. Application To Begin Clinical Trials For Its NGP 555 Compound To Treat And Prevent Alzheimer’s Disease 9/29/2014
CorMedix (CRMD) Announces FDA IND Filing For Neutrolin® In United States 9/25/2014
Medunik Canada Announces Health Canada Priority Review Of PHEBURANE© Indicated For The Treatment Of Urea Cycle Disorders (UCD) 9/25/2014
Emergency Use Of Tekmira Pharmaceuticals Corporation (TKMR)'s Ebola Drug Cleared By FDA, Health Canada 9/24/2014
Fibrocell Science, Inc. And Intrexon Corporation Advance GM-HDF-COL7 Toward Clinical Development For The Treatment Of Recessive Dystrophic Epidermolysis Bullosa 9/24/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1102 For MS Further Development Plans – U.S. FDA Pre-IND Response Timing Confirmed; European Patent Allowance 9/16/2014
Sangamo BioSciences, Inc. (SGMO) Announces Target Date For First IND For Sangamo's In Vivo ZFN Genome-Editing Platform For Monogenic Diseases 9/10/2014
Molecular Templates Inc. Templates Announces FDA Approval Of Investigational New Drug Application For CD20 Internalizing Immunotoxin MT-3724 9/8/2014
Cellectar Biosciences  (NVLT) Announces Acceptance Of Investigational New Drug Application To Evaluate I-131-CLR1404 In Clinical Trials In Relapsed Or Refractory Multiple Myeloma 9/4/2014
Glenmark Pharmaceuticals Enters Oncology With The Discovery And Initiation Of IND Enabling Studies Of An Innovative Bispecific Antibody 8/20/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces FDA Acceptance Of IND To Commence Clinical Trial Of VC-01™ Candidate Cell Replacement Therapy For Type 1 Diabetes 8/19/2014
FDA Grants Orphan Drug Designation For Oncosynergy's Investigational Monoclonal Antibody OS2966 In The Treatment Of Glioblastoma 8/12/2014
Phosphagenics Limited (POH.AX) Completes First IND Enabling Study For TPM(R) / Oxymorphone Patch 8/11/2014
Cellectar Biosciences  (NVLT) Files Investigational New Drug Application To Evaluate I-131-CLR1404 In Clinical Trials In Relapsed Or Refractory Multiple Myeloma 8/11/2014



//-->